外泌体与肝癌化疗药物耐受的进展  

Advances in exosomes and chemotherapeutic drug tolerance in hepatocellular carcinoma

作　　者：任超逸[1] 柳丽丽[1] 单士岗 王毅军[1] Ren Chaoyi;Liu Lii;Shan Shigang;Wang Yijun(Tianjin Third Central Hospital,Tianjin 300170)

机构地区：[1]天津市第三中心医院,天津300170

出　　处：《天津药学》2023年第3期68-74,共7页Tianjin Pharmacy

基　　金：天津市卫健委科技人才培养项目(No.KJ20134)。

摘　　要：肝细胞癌(HCC)是一种常见的恶性肿瘤,在全球癌症相关病死率中居首位。尽管治疗方案有所进展,但由于肿瘤转移、复发和化疗耐药,中晚期肝癌患者的临床治疗效果仍然不理想。外泌体是多种生物活性的细胞间通讯物,在肝癌的进展中发挥着重要作用。越来越多的证据表明,肿瘤微环境(TME)中的外泌体,以及其他细胞外小泡(EV)和细胞因子,有助于肿瘤细胞的药物敏感性。本文从外泌体介导的药物外排和失活、外泌体参与上皮-间充质转化(EMT)诱导的肝癌化疗耐药、肝细胞癌中的外泌体与免疫治疗耐药性等方面进行了阐述,并对外泌体介导的化疗耐药性进行了展望。总之,TME相关的外泌体可能是逆转肝癌患者化疗耐药的潜在靶点和药物疗效的候选生物标志物。Hepatocellular carcinoma(HCC)is a common malignancy that leads the world in cancer-related mortality.Despite advances in treatment regimens,the clinical efficacy of patients with advanced liver cancer is still unsatisfactory due to tumor metastasis,recurrence,and chemotherapy resistance.Exosomes are a variety of bioactive intercellular communications and play an important role in the progression of liver cancer.There is growing evidence that exosomes in the tumor microenvironment(TME),as well as other extracellular vesicles(EVs)and cytokines,contribute to drug sensitivity in tumor cells.In this review,we discussed the exosome-mediated drug efflux and inactivation,the involvement of exosomes in epithelial-mesenchymal transformation(EMT)induced chemotherapy resistance in HCC,and the exosome and immunotherapy resistance in HCC.We also discussed the prospect of exosome-mediated chemotherapy resistance.In conclusion,TME-associated exosomes may be potential targets for reversing chemotherapy resistance and candidate biomarkers for drug efficacy in HCC patients.

关 键 词：肝细胞癌 化疗耐药 外泌体 肿瘤微环境 

分 类 号：R965[医药卫生—药理学] R735.7[医药卫生—药学]